. Furthermore, we developed a handheld pressure controller to drive fluid flow, enhancing the operability of our platform outside of central laboratories and enabling near-patient testing. Our platform can be integrated with downstream cell-based assays and analytical methods that require high leukocyte purity (80%), ranging from cell counting to diagnostics and cell culture applications.
No takes yet. Share an insight, caveat, or question.
Chavez‐Pineda et al. (2024) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: